Cantargia Extends Licensing Agreement with BioWa for its POTELLIGENT Technology

 Cantargia Extends Licensing Agreement with BioWa for its POTELLIGENT Technology

Cantargia Extends its Licensing Agreement with BioWa for its POTELLIGENT Technology

Shots:

  • The extended agreement allows Cantargia to create and use additional CHO cell lines engineered utilizing BioWa’s POTELLIGENT technology and to develop and commercialize CAN04 developed via CHO cell lines
  • In 2015, Cantargia signed an agreement with BioWa’s technology in advancing its CAN04 to P-IIa clinical study for the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer (PDAC)
  • CAN04 (nidanilimab) targeting IL1RAP, currently being evaluated in P-I/IIa CANFOUR study as a monothx. & combination therapy focusing on NSCLC & PDAC. POTELLIGENT technology reduces fucose in the carbohydrate structure of an Ab using fucosyl transferase-knockout CHO cell line thus enhances ADCC activity of an Ab in vitro & increases efficacy in vivo

Click here to­ read full press release/ article | Ref: Business wire | Image: Cision News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post